# KRAScendo 170 (NCT05789082)

> A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05789082
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Divarasib; Pembrolizumab; Carboplatin; Cisplatin; Pemetrexed
- Enrollment: 320
- Primary outcome: Percentage of Participants with Adverse Events (AEs)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=krascendo-170-nct05789082